tóng-àn:Immunotherapy + Durvalumab + Pembrolizumab + Ipilimumab + Atezolizumab mechanism of action.jpg
Seng khoàⁿ chiàm-liōng: 800 × 443 siōng-sò͘. Kî-thaⁿ--ê kái-sek-tō͘: 320 × 177 siōng-sò͘ | 640 × 355 siōng-sò͘ | 1,024 × 568 siōng-sò͘ | 1,694 × 939 siōng-sò͘.
Choân kái-sek-tō͘ (1,694 × 939 siōng-sò͘ , tóng-àn chiàm-liōng: 164 KB, MIME luī-hêng: image/jpeg)
Tóng-àn le̍k-sú
Chhi̍h ji̍t-kî/sî-kan, khoàⁿ hit sî-chūn--ê tóng-àn.
Ji̍t-kî/Sî-kan | 細張圖 | 寸尺 | Iōng-chiá | Chù-kái | |
---|---|---|---|---|---|
hiān-chāi | 2021-nî 11-goe̍h 10-ji̍t (pài-saⁿ) 03:15 | 1,694 × 939(164 KB) | Sannecola | Uploaded a work by Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya 3ORCID from Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals 2020, 13(11), 373; https://doi.org/10.3390/ph13110373 with UploadWizard |
Iáⁿ-siōng liân-kiat
Í-hā ê ia̍h liân kàu chit ê iáⁿ-siōng:
tóng-àn hō͘ lâng sái--ê chōng-hóng
Ē-kha--ê kî-thaⁿ wiki ēng tio̍h chit--ê tóng-àn:
- en.wikipedia.org hō͘ lâng ēng--ê chêng-hêng
- ja.wikipedia.org hō͘ lâng ēng--ê chêng-hêng